Dual action of pyrimidine derivatives: Targeting tamoxifen resistance in breast cancer
Pyrimidine-based TRX-01 and TTP-5 lead structures are promising agents for inhibiting the progression of TAM-resistant breast cancer cells. These results support the need for additional comprehensive in vivo and clinical studies to confirm the efficacy and safety of these compounds.
Authors
- Akshay Ravish
- Sulaiman Ali Alharbi (ORCID: https://orcid.org/0000-0002-4196-2746)
- Basappa Basappa (ORCID: https://orcid.org/0000-0002-8844-468X)
- Arunachalam Chinnathambi (ORCID: https://orcid.org/0000-0001-5075-5901)
- Narasimha M. Beeraka (ORCID: https://orcid.org/0000-0001-6879-7835)
- Vladimir N. Nikolenko
- Kanchugarakoppal Subbegowda Rangappa (ORCID: https://orcid.org/0000-0003-0572-6305)
- Qun Wang (ORCID: https://orcid.org/0000-0001-7929-7692)
- Geng Wang (ORCID: https://orcid.org/0000-0002-6780-0075)
- Yang Li (ORCID: https://orcid.org/0000-0001-9612-2704)
- Jie Yuan (ORCID: https://orcid.org/0009-0008-5209-3874)
- Hua Zhang (ORCID: https://orcid.org/0000-0002-8406-8373)
- Danfeng Zhang
- Minghua Wang (ORCID: https://orcid.org/0000-0003-4067-1127)
Institutions
- Hubei University of Medicine (CN)
- Sechenov University (RU)
- University of Mysore (IN)
- King Saud University (SA)
- Taihe Hospital (CN)
Publication Details
- Journal
- Translational Oncology
- Published
- 2025-06-03
- DOI
- https://doi.org/10.1016/j.tranon.2025.102418
- Citations
- 1
- Primary Topic
- Synthesis and biological activity
- Type
- article
- Field-Weighted Citation Impact
- 0.94